Clinuvel Pharmaceuticals (ASX:CUV) refocused resources to prioritize its three key areas of clinical development: vitiligo, adrenocorticotropic hormone, and porphyrias, according to a Monday filing with the Australian bourse.

The decision is based on the need to optimize the company's internal resources, the likelihood of reimbursement for treatments, and new clinical guidelines related to central nervous system disorders.

The company also temporarily suspended its clinical programs in stroke, Parkinson's disease, and xeroderma pigmentosum, the filing said.

Clinuvel Pharmaceuticals will also continue to develop its non-pharmaceutical photocosmetic products.

The company's shares fell almost 1% in recent Monday trade.

Price (AUD): $13.20, Change: $-0.08, Percent Change: -0.60%